Free Trial

Bank Julius Baer & Co. Ltd Zurich Takes Position in BioNTech SE (NASDAQ:BNTX)

BioNTech logo with Medical background
Remove Ads

Bank Julius Baer & Co. Ltd Zurich purchased a new stake in BioNTech SE (NASDAQ:BNTX - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 56,680 shares of the company's stock, valued at approximately $7,128,000.

Several other institutional investors also recently made changes to their positions in BNTX. FMR LLC grew its holdings in shares of BioNTech by 797.8% during the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company's stock worth $748,243,000 after purchasing an additional 5,598,190 shares during the period. Fred Alger Management LLC purchased a new position in BioNTech in the third quarter valued at approximately $59,485,000. Braidwell LP acquired a new position in BioNTech during the third quarter valued at approximately $29,425,000. abrdn plc grew its stake in BioNTech by 70.7% during the fourth quarter. abrdn plc now owns 385,668 shares of the company's stock worth $43,947,000 after buying an additional 159,676 shares during the period. Finally, Redmile Group LLC acquired a new stake in shares of BioNTech in the third quarter worth $18,345,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on BNTX shares. BMO Capital Markets upped their price target on shares of BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a research report on Tuesday. Citigroup began coverage on BioNTech in a research report on Thursday. They issued a "buy" rating and a $145.00 target price for the company. Evercore ISI upgraded BioNTech from an "in-line" rating to an "outperform" rating and increased their target price for the company from $110.00 to $125.00 in a research note on Tuesday, November 19th. Canaccord Genuity Group reissued a "buy" rating and set a $171.44 price target on shares of BioNTech in a research report on Tuesday. Finally, Berenberg Bank started coverage on shares of BioNTech in a research report on Tuesday, November 19th. They issued a "buy" rating and a $130.00 price objective for the company. Three analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, BioNTech presently has a consensus rating of "Moderate Buy" and a consensus price target of $143.73.

Remove Ads

Read Our Latest Stock Report on BioNTech

BioNTech Stock Performance

BNTX stock traded down $2.84 during trading on Thursday, hitting $97.47. 676,999 shares of the company's stock traded hands, compared to its average volume of 807,990. The stock has a fifty day moving average price of $116.18 and a two-hundred day moving average price of $113.04. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49. The stock has a market capitalization of $23.37 billion, a price-to-earnings ratio of -46.41 and a beta of 0.30.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.38 by $0.70. The firm had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. BioNTech's revenue was down 19.5% on a year-over-year basis. During the same quarter last year, the company posted $1.90 earnings per share. As a group, equities analysts anticipate that BioNTech SE will post -3.88 EPS for the current fiscal year.

About BioNTech

(Free Report)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

Featured Articles

Institutional Ownership by Quarter for BioNTech (NASDAQ:BNTX)

Should You Invest $1,000 in BioNTech Right Now?

Before you consider BioNTech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioNTech wasn't on the list.

While BioNTech currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last
Best ETFs for Spring 2025: Strong and Steady Investing

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads